Loss of endogenous thymosin β<sub>4</sub> accelerates glomerular disease.

Vasilopoulou, Elisavet; Kolatsi-Joannou, Maria; Lindenmeyer, Maja T; White, Kathryn E; Robson, Michael G; Cohen, Clemens D; Sebire, Neil J; Riley, Paul R et al. · Kidney Int · 2016

basic_science · Level V

Where this comes from

Abstract

Glomerular disease is characterized by morphologic changes in podocyte cells accompanied by inflammation and fibrosis. Thymosin β<sub>4</sub> regulates cell morphology, inflammation, and fibrosis in several organs and administration of exogenous thymosin β<sub>4</sub> improves animal models of unilateral ureteral obstruction and diabetic nephropathy. However, the role of endogenous thymosin β<sub>4</sub> in the kidney is unknown. We demonstrate that thymosin β<sub>4</sub> is expressed prominently in podocytes of developing and adult mouse glomeruli. Global loss of thymosin β<sub>4</sub> did not affect healthy glomeruli, but accelerated the severity of immune-mediated nephrotoxic nephritis with worse renal function, periglomerular inflammation, and fibrosis. Lack of thymosin β<sub>4</sub> in nephrotoxic nephritis led to the redistribution of podocytes from the glomerular tuft toward the Bowman capsule suggesting a role for thymosin β<sub>4</sub> in the migration of these cells. Thymosin β<sub>4</sub> knockdown in cultured podocytes also increased migration in a wound-healing assay, accompanied by F-actin rearrangement and increased RhoA activity. We propose that endogenous thymosin β<sub>4</sub> is a modifier of glomerular injury, likely having a protective role acting as a brake to slow disease progression.

Medical subject headings